CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Lumasondrug
Likely dose
Lumason 2.4 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04569799
NCT04569799Phase 4Completed
CompareCT.gov

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma (HCC) Post Transcatheter Arterial Chemoembolization (TACE)

Milton S. Hershey Medical Center·interventional·Posted Sep 30, 2020·Updated Nov 2, 2023

In Brief

A Phase 4 clinical trial evaluating Lumason for Hepatocellular Carcinoma. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC) after receiving TACE treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedSep 30, 2020
Enrollment StartOct 14, 2020
Primary CompletionOct 11, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.8 years ago

Interventions

Lumasondrug

2.4 mL per lesion